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Introduction
Haemophilia A is an inherited, sex-linked disorder in
which coagulation factor VIII (FVIII) is deficient or
absent [1]. The hallmark of the severe form of the
disease, defined as plasma FVIII level of <1% of
normal [2], is early, recurrent bleeding into soft
tissues and joints [3]. Intra-articular bleeding (haem-
arthrosis) accounts for more than 90% of all serious
bleeding events in patients with severe haemophilia,
and 80% of these bleeds involve the knees, elbows
and ankles [1]. An acute haemarthrosis is typified by
rapid joint swelling that may be preceded by a
prodrome of tingling, stiffness and pain (Fig. 1)
[4,5]. Recurrent bleeding over time into the same
joint (a target joint) results in progressive joint
damage and the development of haemophilic
arthropathy, characterized by synovial hypertrophy,
cartilage damage, loss of joint space and bony
changes (Fig. 2) [6,7]. Decreased use of a target joint
leads to ongoing muscle atrophy, ankylosis, osteo-
porosis, bone cysts, and eventually, crippling arthri-
tis by young adulthood [3,7].
The development of arthropathy is directly linked to
the number of joint bleeding episodes [8,9]. In the
landmark Orthopaedic Outcome Study, which en-
rolled 378 patients with severe haemophilia A,
Aledort et al. reported the Pettersson radiologic scores
increased 1 point for every 40 joint bleeds [8]. A
subsequent evaluation by Fischer et al. of 117 severe
haemophilia patients found that far fewer bleeds – just
13 – were necessary to cause a 1 point increase in the
Pettersson score [9]. Yet even this lower number may
be an overestimate. A major limitation to the use of
plain film radiographs as a tool for assessing arthro-
pathy is their ability to visualize only gross arthritic
alterations [1]. When magnetic resonance imaging
(MRI) was performed on children with haemophilia
who had no obvious clinical signs of arthropathy,
early changes in the soft tissues (e.g., synovium and
cartilage) were demonstrated [1]. These MRI findings
indicate that incipient joint damage may occur after
very few bleeding episodes.
On-demand therapy (episodic factor replacement
in response to acute bleeding events), while effective
in controlling acute haemorrhage, cannot halt the
ongoing joint destruction many patients with severe
haemophilia A experience [10]. An epidemiologic
survey conducted by the French Study Group of 116
haemophilia patients treated almost exclusively from
birth with on-demand therapy found that at a mean
age of 23 years, only 3.7% had normal joints by
radiographic examination and 54.3% had undergone
orthopaedic procedures [11]. Similarly dismal long-
term outcomes were reported by Blanchette. Among
patients with severe haemophilia managed in Canada
with on-demand therapy, approximately 50% had
evidence of joint disease by age 13 years; and by age
18, 24% of the 54 patients had undergone surgical
synovectomy of at least 1 joint [12].
For children with severe haemophilia A and no
evidence of inhibitors, the musculoskeletal compli-
cations that follow repeated joint bleeding can be
effectively prevented with the early initiation of
prophylaxis, the routine scheduled replacement of
FVIII with the goal of maintaining FVIII trough
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levels above 1% [10,13–21]. Nonetheless, surveys of
international practice patterns [22,23] and statistics
from the Universal Data Collection Programme [24]
indicate that the majority of patients with severe
FVIII deficiency continue to receive on-demand
therapy. In an effort to optimize outcomes in patients
with severe haemophilia A through increasing the use
of prophylaxis, a panel of clinicians from haemo-
philia treatment centres (HTCs) in North America
convened in Miami, Florida, on January 27–28,
2007, to review the current state of knowledge about
joint-protective therapeutic approaches and from
this derive best treatment strategies. We hope that
the information presented in this supplement,
which summarizes our review of the literature and
subsequent discussions and recommendations, will
help physicians and their staffs develop protocols for
the use of prophylaxis in children, adolescents and
adults with severe haemophilia A.
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Initiating prophylaxis in children
Data supporting prophylaxis
The rationale for prophylaxis is predicated on
observations published by Swedish researchers more
than 40 years ago. They reported that maintaining
FVIII plasma levels between 1% and 3% of normal
appeared to convert patients from a severe to a
moderate haemophilia A phenotype, in which spon-
taneous bleeding events are less frequent and mus-
culoskeletal complications are less likely to occur
[25,26]. In the ensuing years, several observational
studies demonstrated the efficacy of FVIII prophy-
laxis in preventing joint bleeding and the subsequent
development of arthropathy, target joints and dis-
ability [8,13–20]. Moreover, the benefits of prophy-
laxis extended beyond joint protection and included
preventing other serious or life-threatening haemor-
rhages, such as recurrent central nervous system









Fig. 1. Acute hemarthrosis. The right (R) knee is swollen, warm
and painful to touch. Range of motion is limited. Palpation of the





Fig. 2. Chronic synovitis and arthropathy. (a) Chronic synovitis of
the right (R) knee is typified by a warm and swollen joint with
reduced range of motion but no pain with palpation or motion.
Palpation of the joint margins and patella are obscured by the
spongy synovium, and muscle atrophy is present. (b) Radiograph
of the knee showing narrowing of the joint space, erosions at the
margins, sclerosis, osteoporosis, a widened intra-condylar notch
and cyst formation.
2 S. W. PIPE and L. A. VALENTINO
Haemophilia (2007), 13 (Suppl. 4), 1–16  2007 Scienta Healthcare Education
[16,27], and indirectly improving academic perfor-
mance [28] and quality of life (QOL) [19,20].
Because of these advantages, prophylaxis is recom-
mended as optimal therapy for patients with severe
haemophilia A by the National Hemophilia Founda-
tion (NHF) [29], the World Federation of Hemo-
philia (WFH) [30] and the World Health
Organization (WHO) [31].
While the empiric benefits of prophylaxis have
been clear for decades, a key piece of information
was missing: results from a randomized controlled
trial (RCT). Because of this deficit, a systematic
review conducted by the Cochrane Collaboration
concluded that there was insufficient evidence to
determine the effectiveness of prophylaxis in decreas-
ing the frequency of joint bleeding [32]. Fortunately,
the deficiency of RCT data has been rectified. In
August 2007, Manco-Johnson published the findings
from the prospective, controlled US Joint Outcome
Study [10]. This trial enrolled 65 children between
12 and 30 months of age with severe haemophilia A
randomized to a prophylactic regimen of every-
other-day FVIII infusions of 25 IU kg)1 (n = 32) or
enhanced episodic therapy consisting of three or
more FVIII infusions totalling at least 80 IU kg)1 to
treat joint haemorrhages (n = 33). At the end of the
5-year follow-up period, joint bleeding was signifi-
cantly lower in the prophylaxis group compared with
the enhanced episodic therapy group: 0.47 bleeds
annually vs. 4.9 bleeds annually respectively
(P < 0.001). The favourable results from the first
RCT of primary prophylaxis coupled with more than
four decades of observational studies have now
firmly established the efficacy of this treatment
strategy.
Primary prophylaxis
Only a few joint bleeds may cause damage [33], and
arthropathy, once established, does not reverse
and may progress despite the use of prophylactic
treatment [14]. Consequently, all children with
severe haemophilia A ideally should be placed on
primary prophylaxis. Primary prophylaxis is variably
defined [34–36], but a commonly used definition
developed by an international consensus panel
describes it as long term, continual treatment started
before the age of 2 years and prior to any clinically
evident joint bleeding or started after the first joint
haemorrhage, irrespective of age (Table 1) [35].
Whether primary prophylaxis should be started
before the first joint haemorrhage or shortly thereafter
remains a matter of debate. One argument for
initiating treatment between 1 and 2 years of age
and before the first bleeding event is that some children
have developed joint disease despite no history or
awareness of haemarthrosis [37]. This finding suggests
that even subclinical joint bleeding may lead to slowly
progressive arthropathy and underscores the need for
early intervention. On the other hand, starting pro-
phylaxis at a very young age is costly, can result in over
treatment of a group of children who are not prone to
haemarthroses despite low levels of endogenous FVIII,
and often requires insertion of a central venous access
device (CVAD) to administer factor [35]. Further-
more, patients on prophylaxis still experience joint
bleeding [8,18,19], indicating that starting prophy-
laxis before the first bleeding episode can postpone
haemarthrosis but does not entirely prevent it.
Marked variability in the severe haemophilia
clinical phenotype has been described [8,38–41]
and is well known to treating physicians. For patients
with a milder phenotype, it may be possible to safely
delay the initiation of primary prophylaxis until later
in life [41]. Some HTCs allow a child to experience a
few episodes of joint bleeding before embarking on a
prophylactic regimen, as this gives the clinician an
opportunity to observe the bleeding pattern [42] and
also impress upon the parents the adverse impact of
bleeding.
While the question of when to start primary
prophylaxis remains unresolved, there is no debate
Table 1. Definitions of primary and secondary prophylaxis.
Type of prophylaxis Definition
Primary prophylaxis determined by age [35] Long-term continual* treatment started before age 2 years
and prior to clinically evident joint bleeding
Primary prophylaxis determined by
first bleeding episode [35]
Long-term continual* treatment started prior to the onset
of joint damage (presumptively defined as not more than
one joint haemorrhage), irrespective of age
Secondary prophylaxis [35,42] Long-term continual* prophylaxis initiated after multiple
joint bleeds and the onset of joint damage
*With the intent of treating 52 weeks per year up to adulthood and receiving treatment a minimum of 46 weeks per year.
Adapted with permission from Berntorp E, Astermark J, Bjorkman S et al. Consensus perspectives on prophylactic therapy for haemo-
philia: summary statement. Haemophilia 2003; 9(Suppl. 1): 1–4.
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about the importance of initiating treatment after no
more than a few joint haemorrhages. A study by
Fischer et al. that followed 76 patients with severe
haemophilia A for 20 years showed that the Petters-
son score was 8% higher for every year prophylaxis
was postponed after the first episode of haemarthro-
sis [43].
Recommendations for primary prophylaxis
Prophylaxis should be initiated in all patients with
severe haemophilia A before 2 years of age and prior
to clinically evident joint bleeding or after no more
than a few joint haemorrhages (to establish the
bleeding phenotype).
Secondary prophylaxis
Despite the clear advantages of primary prophylaxis,
this treatment strategy remains underutilized
[23,24]. However, a substantial segment of the
haemophilia population can still benefit from pro-
phylactic treatment when administered in the form of
secondary prophylaxis, defined as long term, contin-
uous prophylaxis initiated after multiple joint bleeds
(Table 1) [35].
Secondary prophylaxis can reduce joint and other
bleeding episodes; slow the progression of, although
not reverse, existing joint damage; and permit
participation in sports and other activities [44–48].
It also allows aggressive physical rehabilitation to be
undertaken in children and adolescents with chronic
joint damage [44]. The magnitude of the benefits of
secondary prophylaxis depends on the number of
previous bleeding episodes and the extent of pre-
existing joint damage, which generally correlate with
patient age at the start of prophylaxis [44]. The
earlier the prophylactic regimen is started, the better
the outcome. Nonetheless, the advantages of pro-
phylaxis are seen regardless of the age at initiation
[48]. In other words, it is never too late to start.
Although patients with severe haemophilia have the
highest frequency of bleeding episodes, a subgroup of
patients with moderate haemophilia, defined as a
FVIII level of 1–5% of normal [2], also experience
regular haemarthroses and develop target joints,
arthropathy and impaired mobility while receiving
on-demand therapy (Fig. 3) [24]. These individuals
may also benefit from secondary prophylaxis.
Recommendations for secondary prophylaxis
1 In patients with severe haemophilia A in whom
primary prophylaxis has been delayed, secondary
prophylaxis should be initiated as soon as possi-
ble, even after the onset of joint damage (it is never
too late to start).
2 Secondary prophylaxis should be considered in
patients with moderate haemophilia A who expe-
rience frequent joint haemorrhages.
Prophylactic regimens
Three basic prophylactic regimens have been de-
scribed that differ with regard to dose, dosing
frequency and whether treatment is initiated on the
basis of age or after joint bleeding has occurred
(Table 2) [14,49,50].
Full-dose prophylaxis (Malmö regimen)
Prophylaxis for severe haemophilia A was first
utilized in Malmö, Sweden, in 1958 [14]. Treatment
has intensified over the years, and in the current
regimen, FVIII is administered at a dose of 25–
40 IU kg)1 three times weekly starting at age 1–
2 years, irrespective of bleeding history [18]. The
goal is to maintain FVIII coagulant activity (FVIII:C)
above 1% of normal at all times. Pharmacokinetic
measurements are used to guide dosing.
In 1992, Nilsson et al. described 25 years of
experience with prophylaxis in 60 Swedish patients,
aged 3–32 years, with severe haemophilia A or B
[14]. Patients in the two youngest age groups, who
received full-dose primary prophylaxis at a very early
age, had better outcomes than the oldest group of
patients, some of whom had joint damage when
secondary prophylaxis was started, initially at lower
doses. Specifically, boys aged 3–12 years (n = 15)
experienced almost no bleeding episodes, had ortho-
paedic scores (Table 3) and radiologic scores
(Table 4) of zero (0/0), and were able to lead normal
lives. In comparison, patients aged 18–32 years
(n = 25) had 0.5–16 joint haemorrhages annually,
and only four had joint scores of 0/0. Nonetheless,
patients who received any level of prophylaxis had
better joint outcomes than patients in the on-demand
therapy group.
In 1997, the Malmö group published follow-up
data that showed that the youngest treatment groups
(n = 15) still had not experienced any haemarthrosis,
and their orthopaedic and radiologic joint scores
remained 0/0 [18]. Despite treatment intensification,
episodes of joint bleeding persisted in the oldest
patient groups (n = 19). This finding confirms that
prophylaxis can slow, but not halt, progressive
arthropathy in patients with pre-existing joint disease.
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The Medical and Scientific Advisory Council [29]
of the NHF recommends a slightly modified version
of the Malmö regimen for prophylaxis: FVIII 25–
50 IU kg)1 three times weekly or every other day,
instituted before the onset of frequent bleeding.
Intermediate-dose prophylaxis (Dutch regimen)
In the Netherlands, prophylaxis is usually started
after the occurrence of at least one episode of joint
bleeding [49]. As in Sweden, dosing has been
intensified over the years, and the current interme-
diate-dose prophylactic regimen for patients with
haemophilia A is FVIII 15–25 IU kg)1 infused two or
three times weekly. Dosing is adjusted in the event of
spontaneous breakthrough bleeds, but FVIII trough
levels are not considered when making the adjust-
ments.
To determine the impact of different dosing
regimens on long-term outcomes, Fischer et al.
retrospectively compared 86 Dutch haemophilia
patients treated with intermediate-dose prophylaxis
beginning at a median age of 5 years with 42
Swedish haemophilia patients treated with full-dose
prophylaxis beginning at a median age of 2 years
[49]. After a median of 17 years of follow-up, the
annual number of joint bleeds (adjusted for age) was
77% lower in patients treated with the high-dose
regimen (median, 0.3/year vs. 3.3/year). The Petters-
son score (Table 4) was also lower in the high-dose
group (median, 0) vs. the intermediate dose group
(median, 4), although the reduction in arthropathy as
measured by the Pettersson score was not statistically
significant (P = 0.560 or P = 0.797, depending on
year of birth). No statistical differences in outcome,
as measured by the Gilbert orthopaedic joint score
promoted by the WFH (Table 3) or the physical
domains of the SF-36 [51] (a multipurpose, short-
form generic health-related QOL survey) emerged,
and according to the investigators, prophylaxis
enabled patients in both countries to lead normal
lives, including participation in sports. Substantial
Table 2. Regimens used for primary prophylaxis [14].
Regimen FVIII dose (IU kg)1) Frequency Determinant of when prophylaxis is started
Full-dose (Malmö regimen) 24–40 tiw Age
Intermediate-dose (Dutch regimen) 15–25 biw or tiw Bleeding pattern (usually
after first joint haemorrhage)
Tailored-dose (Canadian regimen) Step 1: 50 qw Age
Step 2: 30 biw
Step 3: 25
5-IU kg)1 incremental increases
if bleeding continues
qod
Fig. 3. Joint complications in patients ‡2 years by haemophilia severity [24].
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differences were noted in the cost of the two
prophylactic regimens. Because prophylaxis was
started earlier and administered in larger doses in
the Swedish cohort, the consumption of clotting




The clinical manifestations of severe haemophilia A
are variable [8,41], and there is considerable dispar-
ity in prophylactic dosing requirements due to
interpatient differences, including the pharmacoki-
netics of FVIII:C [38,53,54]. Individualized dosing
that is adjusted according to a patients bleeding
pattern offers an opportunity to provide adequate
prophylactic coverage while reducing FVIII con-
sumption [55].
A tailored-dose regimen developed by the Cana-
dian Prophylaxis Study Group initiates FVIII pro-
phylaxis at 50 IU kg)1 once weekly (step 1) [50]. The
dose and frequency are increased to 30 IU kg)1 twice
weekly if the patient develops target joint bleeding
(‡3 bleeds into a single joint during a consecutive 3-
month period), experiences excessive bleeding (de-
fined by the investigators as ‡4 joint or soft tissue
haemorrhages during a consecutive 3-month period),
or has five or more haemorrhages into a single joint
over any period of time (step 2). Dosing is further
increased to 25 IU kg)1 every other day if any of the
escalation criteria recur while on step 2 (step 3).
Additional incremental increases of 5 IU kg)1 are
prescribed if bleeding continues. This regimen was
evaluated in 25 boys aged 1–2.5 years with severe
haemophilia A, none of whom had a history of target
joint bleeding [50]. After 5 years, 10 patients con-
tinued to receive once-weekly prophylaxis, eight
patients had escalated to step 2 and received twice-
weekly prophylaxis, and seven patients required full-
dose alternate-day prophylaxis (having escalated
from step 1 to 2 to 3). A total of 116 joint
haemorrhages occurred during the study period, an
average of 1.2 per person-year. Nine patients (36%)
developed target joints within 3.5 years of starting
prophylaxis, suggesting that the trade-off to this
lower intensity regimen may be that some patients
experienced frequent bleeding. However, dosing was
escalated when this occurred, and no subject devel-
oped a second target joint. Furthermore, half of the
patients have not required escalation, which has
resulted in substantial savings on factor concentrate
and, possibly, improved QOL compared with more
intensive regimens. The ultimate impact of allowing
patients to manifest some bleeding episodes before
dosage escalation awaits long-term studies.
Recommendations for the prophylaxis dosing regimen
1 Optimal prophylaxis requires the administration
of FVIII 25–40 IU kg)1 three times weekly or
every other day, instituted before the onset of
frequent bleeding.
2 In certain cases, individualized dosing regimens
that provide adequate prophylactic coverage can
be considered in an effort to reduce FVIII con-




Although in vivo pharmacokinetic measurements of
FVIII are used in the Malmö regimen to ensure that
trough levels exceed 1% of normal between prophy-
lactic infusions [14,18], the correlation between
FVIII levels and the incidence of joint bleeding is
very weak [53]. A retrospective survey of medical
records from the Malmö HTC over a 6-year period
found that some patients with trough levels below
Table 4. Radiologic joint score (Pettersson score) [52].
Type of change Finding Score*
Osteoporosis Absent 0
Present 1
Enlarged epiphysis Absent 0
Present 1
Irregular subchondral surface Absent 0
Partially involved 1
Totally involved 2







Subchondral cyst formation Absent 0
1 Cyst 1
>1 Cyst 2
Erosion of joint margins Absent 0
Present 1
Gross incongruence




Joint deformity Absent 0
Slight 1
Pronounced 2
*Maximum possible joint score = 13; maximum possible total
joint score (sum of elbows, knees and ankles) = 78.
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1% experienced no bleeding episodes, while others
bled despite having trough levels exceeding 3%.
Other pharmacokinetic parameters, such as FVIII
recovery and half-life, have been used to detect the
presence of non-neutralizing inhibitory antibodies
[56]. Clinical outcome, not the maintenance of an
arbitrary FVIII trough level, should determine
whether dosing is sufficient and prophylaxis is
effective.
Breakthrough bleeding
Spontaneous breakthrough bleeding may indicate
that the prophylactic regimen is inadequate and
requires adjustment. Breakthrough bleeding drives
dose escalation in both the intermediate-dose and
tailored-dose regimens [49,50]. However, the precise
number of haemorrhages that is indicative of regi-
men failure and the need to intensify treatment is
unknown.
Musculoskeletal assessment
The primary measure of the efficacy of prophylaxis
is the assessment of musculoskeletal status by
physical examination and plain film radiographs
[12]. Two scoring systems are predominantly used.
The orthopaedic joint score (Table 3), recom-
mended by the Orthopaedic Advisory Committee
of the WFH, uses a 15-point scale to evaluate each
elbow, knee and ankle and has a maximum
possible score of 90 [57]. The Pettersson radiologic
score (Table 4) assesses each of these joints on a
13-point scale and has a maximum possible score
of 78 [37]. The two assessments are generally
performed in tandem, and a perfect score is rated
as 0/0.
Limitations of the WFH orthopaedic joint scoring
system are insensitivity to early haemophilic arthrop-
athy and the use of tasks that may be beyond the
developmental ability of young children to perform
[12]. An expanded physical joint evaluation scale
capable of detecting early structural or functional
abnormalities has been developed specifically for
young children with haemophilia [58] and is being
studied in prospective, longitudinal clinical trials.
Similarly, plain film radiographs, the standard tool
for detecting and assessing structural joint damage
associated with haemophilic arthropathy [35], are
not sensitive to early joint damage [1]. As previously
discussed, MRI allows evaluation of soft tissue
changes that precede cartilage and bone destruction
[59]. However, MRI is not cost-effective for routine
clinical monitoring [35].
Health-related quality of life
Effective treatments have increased the life expec-
tancy of patients with haemophilia. Consequently,
improvement in health-related QOL has become one
of the major concerns of haemophilia management
[60]. Disease-specific measures of QOL for children
with haemophilia are available for use in clinical
studies [61] but are not typically used in clinical
practice. Instead, QOL is assessed by asking ques-
tions about the patients general well-being. Ques-
tioning is sometimes augmented with the SF-36
health survey, although this survey has not been
validated for use in children. Because symptomatic
haemophilic arthritis often appears years after the
onset of joint bleeding, QOL measures determined in
young adults are needed to realistically compare the
outcomes of prophylactic regimens used in early
childhood.
Recommendations for measuring prophylaxis
outcomes
Objective assessments of musculoskeletal status and
health-related QOL should be a part of any effort to
evaluate outcomes in patients receiving prophylaxis.
Barriers to prophylaxis
Several barriers to the initiation and continuation of
prophylaxis have been consistently identified in
surveys of practice patterns and include venous
access issues, cost and problems with adherence
[22,23,62].
Venous access issues
Venous access issues are among the top reasons given
for not administering prophylaxis or discontinuing
treatment [22,23]. Venipuncture may be difficult for
caregivers and patients [62], and CVADs, either fully
implantable ports or external catheters [63], are
often needed to facilitate prophylaxis administration
to young children [14,33,50,64].
Infection is the major complication associated with
CVADs used in haemophilia [65], and it is the most
common cause for their removal [63]. In a meta-
analysis of 48 studies that involved 2704 patients
and 2973 CVADs, Valentino et al. found that 44%
of patients and 40% of CVADs were affected by an
infectious episode [63]. Thrombosis may also occur
with CVAD use [63,66]. While this complication
may be silent and clinically insignificant, patients
may manifest severe and potentially life-threatening
8 S. W. PIPE and L. A. VALENTINO
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symptoms, such as superior vena cava syndrome
[67].
An escalating-dose prophylactic regimen is one
strategy for minimizing the need for CVADs [41].
Petrini described a regimen that begins with once-
weekly infusions very early in life to facilitate
peripheral venous access and increases to full-dose
prophylaxis by the time the child reaches 2 years
[41,68]. When a CVAD is necessary, patient and
family education is essential to minimize infectious
risk and should be reinforced on a continuing basis
[63]. Regular monitoring of the patient and CVAD
by the haemophilia treatment team is also required
[66].
Arteriovenous fistulae (AVF), the vascular access
of choice for haemodialysis patients [69], are now
being evaluated as an option for venous access in
boys with haemophilia aged 1 year and older in an
effort to avoid the complications of CVADs. A
prospective study of 27 children with severe
haemophilia found the AVF were regularly and
successfully used at home by 26 patients (96%) for
a median follow-up of 29 months [70]. Venous
thrombosis occurred in one patient after 9 months,
but symptoms spontaneously disappeared, and the
AVF was used for an additional 9 months. McCar-
thy et al. also described the successful use of AVF
in nine haemophilia patients, five of whom had a
total of 21 failed CVADs before the creation of the
AVF [71]. Adapting AVF to the requirements of
children with haemophilia requires surgical exper-
tise and long-term follow-up with ultrasonography
and echocardiography. Once peripheral veins pro-
vide adequate vascular access, the AVF should be
dismantled.
Cost
Prophylaxis allows haemophilia patients to lead
functionally normal and productive lives, but at a
high cost: FVIII consumption for patients treated
with the full-dose Malmö regimen may exceed
8900 IU kg)1 annually [18]. Whether prophylaxis,
as has been suggested, actually lowers overall
healthcare costs by reducing the need for emergency
room visits, hospitalization, orthopaedic interven-
tions and other surgeries [8,16,19,72] is uncertain.
An economic evaluation by Bohn et al. found that
the savings fail to offset the expense of year-round
prophylaxis [73]. A subsequent comparison of
healthcare expenditures by Ullman and Hoots found
that the yearly cost in US dollars for prophylaxis and
on-demand therapy was similar [74]. Outpatient
costs were greater for patients on prophylaxis, but
inpatient costs were higher for those treated on-
demand. However, when costs were adjusted for
body mass, prophylaxis was two to threefold more
expensive than on-demand therapy, confirming the
findings of Bohn et al. that prophylaxis is the more
costly intervention.
Intermediate-dose and tailored-dose regimens have
the potential to appreciably reduce costs by provid-
ing therapeutic benefits similar to those of full-dose
prophylaxis while using lower amounts of factor
[49,50,75]. Not only would these regimens improve
the cost-effectiveness of prophylaxis, but they may
also make optimal therapy available to more patients
with severe haemophilia [76].
Adherence
Poor adherence to the prophylactic regimen is a
significant impediment to optimizing treatment [23].
A global survey of practice patterns identified denial;
a lack of parental or family commitment; and the
time-consuming nature of prophylaxis, which can
interfere with other family needs and social obliga-
tions, as challenges to full adherence [23]. Teenage
rebellion may also contribute to non-adherence, as
evidenced by the fact that adherence is higher in
younger patients whose infusions are administered
by their parents than among adolescents who self-
infuse. Yet the most significant obstacle to adherence
was a lack of understanding of the potential benefits
of prophylaxis. Conversely, knowledge of these
benefits was cited as the primary facilitator of
adherence in a survey of prophylaxis patients and
their families [62]. Ongoing education and support
provided by the haemophilia treatment team are key
to encouraging patients and families to make the
long-term commitment to a demanding treatment
strategy [62,77–79].
Recommendations for overcoming barriers to prophy-
laxis
1 Consider an escalating-dose regimen when initi-
ating prophylaxis to minimize the need for
CVADs in young children.
2 AVF are an option for venous access in some
children (e.g., those who have experienced
repeated CVAD failure).
3 Intermediate- and tailored-dose regimens may
reduce costs while providing therapeutic benefits
similar to those of full-dose prophylaxis.
4 Provide patients and families with on-going edu-
cation and support to facilitate their long-term
commitment to prophylaxis.
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Transitioning to adult care
Historical perspective
In June 1982, the first case of human immunodefi-
ciency virus (HIV) was diagnosed in a US haemo-
philia patient who had no known risk factors [80].
HIV, transmitted by infusions of clotting factor
concentrates, went on to ravage the haemophilia
community (Fig. 4). Early in 1985, the availability of
heat-treated FVIII products halted the clotting fac-
tor-related HIV epidemic [80], but by that time,
more than 50% of haemophilia patients in the
United States had been infected [81]. For many years
thereafter, HIV and hepatitis C (Fig. 5)–not joint
health–were the over-riding concerns of treaters,
patients and families and the leading causes of death.
Consequently, most adults with haemophilia alive
today have never been treated with primary or
secondary prophylaxis.
Difficulties in making the transition from paediatric
to adult prophylaxis
Several factors are implicated in the decline in the use
of prophylaxis in adulthood. First, while many larger
HTCs treat both children and adults, some centres
only have paediatric programmes [82]. Once a child
reaches his late teens, his care may be transferred to
an internist unfamiliar with prophylaxis or unaware
of the importance of continuing the prophylactic
regimen into adulthood. Lifestyle changes also con-
tribute to lower rates of prophylaxis in adults. The
demands of work, family and social activities may
leave little time for regular infusions. Fatigue with
the requirements of prophylaxis is another factor
that may lead to treatment discontinuation, partic-
ularly for patients who started prophylaxis at a very
young age. Finally, the high cost forces some patients
to abandon prophylaxis. Patients who were covered
under their parents health insurance plans may not
have their own insurance as adults. Furthermore,
Medicaid benefits vary from state to state and may
not include haemophilia prophylaxis after age 18.
Should prophylaxis be stopped?
Given the difficulties in maintaining prophylactic
regimens into adulthood, is it possible to stop
prophylaxis at some point? The NHF [29], WFH
[30], and WHO [31] recommend that prophylaxis be
continued, possibly throughout life, as the risk of
traumatic bleeding events persists in adults, the
severity of haemophilia is practically the same as in
childhood, and the benefits of prophylaxis are
experienced by all age groups [76]. On the other
hand, there may be some rationale for stopping
treatment, or a least modifying the regimen. Adults
are usually less physically active than children, so the
likelihood of injury is lower. In addition, there is in
vivo animal data to suggest that mature joint
cartilage is less susceptible to blood-induced damage
than is cartilage in younger joints [83].
Little clinical data exists on the impact of discon-
tinuing prophylaxis in adulthood. van Dijk et al.
reported on 80 patients with severe haemophilia
born between 1970 and 1980 treated with prophy-
laxis in Denmark and the Netherlands [84]. The
median age at the start of prophylaxis was 5.6 years
(Denmark) and 6.0 years (the Netherlands), and the
median follow-up period was 19 years. By the age of
26 years, 35% of the patients from both cohorts had
changed to on-demand treatment, yet they experi-
enced (on average) only three bleeds annually.
Nearly 4 years after the patients discontinued pro-
phylaxis, their joint status, assessed by clinical and
Fig. 5. Prevalence as of 2005 of hepatitis C virus infection among
persons with haemophilia enrolled in UDC [24].
Fig. 4. Prevalence as of 2005 of human immunodeficiency virus
infection among persons with haemophilia enrolled in UDC [24].
10 S. W. PIPE and L. A. VALENTINO
Haemophilia (2007), 13 (Suppl. 4), 1–16  2007 Scienta Healthcare Education
radiologic scores, appeared unaffected and outcomes
were similar to those in patients who remained on
prophylaxis.
A previous report by Fischer et al., which
described only the Dutch cohort, identified charac-
teristics of the subgroup of patients who stopped
prophylaxis [85]. They included a later start of
prophylaxis, a lower weekly dose of FVIII, and
reduced incidence of joint bleeding on prophylaxis,
all of which suggested a milder bleeding pattern.
Although those prognostic features failed to predict
discontinuation of prophylaxis among the Danish
patients described by van Dijk [84], the findings from
both studies indicate that it may be possible to select
candidates for permanent cessation of prophylaxis.
However, prospective trials are needed to determine
whether some patients can safely stop treatment and
to determine the impact of such a change.
Other preventive infusion strategies
Primary or secondary prophylaxis is always the
preferred treatment strategy for severe haemophilia
A, especially for children. For older patients who are
not on continuous prophylactic regimens, other
preventive infusion strategies may prevent serious
bleeding-related sequelae.
Limited prophylaxis
Limited prophylaxis, also referred to as intermittent
or episodic prophylaxis, is defined as a short period
of factor replacement to prevent bleeding in specific
situations (Table 5). Surgery is the classic example of
limited prophylaxis. Other situations where limited
prophylaxis may be considered include prior to
participating in sports or other strenuous activities;
during travel, particularly if the patient will not have
rapid access to high-quality medical care; and before
special events, such as college final exams or a
wedding.
There is minimal data on limited prophylaxis
outside the surgical setting. In a UK pilot study, four
adults with severe haemophilia A and arthropathy
received factor sufficient to raise FVIII levels to 20%
prior to each session of physical therapy [86]. Over a
2-year period, the patients experienced an 89% mean
reduction in the number of bleeding episodes; general
improvement in joint condition; improved QOL, as
evidenced by increased activity and decreased pain
and an overall reduction in annual FVIII usage.
The goal of limited prophylaxis is to completely
prevent bleeding; to this end, aggressive dosing to
achieve 100% correction may be required. For
patients with severe haemophilia A, the panel
recommended a dose of 50 IU kg)1 prior to the
activity or event, with dosing repeated for multiple-
day activities. Patients with mild haemophilia may
also benefit from limited prophylaxis with desmo-
pressin acetate, although the risks of hyponatremia
and tachyphylaxis limit multiple-day dosing [87].
Short-term secondary prophylaxis to prevent
recurrent bleeding following major haemorrhage,
such as ICH or other traumatic injury, is another
form of limited prophylaxis (Table 5). While the
optimal dose and duration of therapy in this setting is
unknown, several weeks–if not months–of treatment
may be needed to prevent rebleeding into an injured
area [88].
Intensive on-demand therapy
Most clinical trials have demonstrated that the vast
majority of acute bleeding events in severe haemo-
philia can be managed with 1–2 on-demand infu-
sions that achieve a target plasma correction of
approximately 50% [89–91]. However, certain types
of haemorrhages may require higher target plasma
levels sustained over a longer duration of time.
Intensive on-demand therapy refers to the adminis-
tration of factor at higher-than-usual doses and
frequency and for a longer-than-usual duration to
achieve haemostatic FVIII levels during bleeding
episodes (Table 5). Intensive on-demand therapy
has been used for the management of ICH [92,93]
and may also be appropriate for certain joint, muscle
and other bleeding events in patients with severe
haemophilia A who are not on prophylaxis [94].
Table 5. Definitions of other infusion strategies.
Type of infusion strategy Definition
Limited prophylaxis Short period of factor replacement to prevent bleeding in specific situations
Short-term secondary prophylaxis Prophylaxis administered for a limited period to prevent
recurrent bleeding following a major haemorrhage
Intensive on-demand therapy Administration of factor at higher-than-usual doses,
more frequent intervals, and for a longer-than-usual duration
to achieve a haemostatic FVIII level during bleeding
episodes in patients not on prophylaxis
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A variety of dosing regimens has been used for this
type of on-demand therapy, some of which are more
intensive than others [95]. In the US Joint Outcome
Study, intensive on-demand therapy consisted of at
least three FVIII infusions totalling at least 80 IU kg)1
[10]. While this study showed that on-demand therapy
was inferior to prophylaxis, it was not designed to
assess the efficacy of intensive vs. standard dosing.
The panel recommended that when intensive on-
demand therapy is desirable, an 80%-100% correc-
tion of the FVIII level should be targeted, rather than
the standard 50%-60% correction (Table 6). Sub-
sequent doses aimed at a 50%-100% correction
should be given for persistent symptoms (e.g. pain,
swelling, decreased range of motion) and adminis-
tered at least every 12 hours.
Recommendationsforotherpreventive infusionstrategies
1 Primary or secondary prophylaxis is always pre-
ferred for patients with severe haemophilia A.
2 Limited prophylaxis to prevent bleeding in specific
situations may require 100% correction to com-
pletely prevent bleeding.
3 Weeks, if not months, of short-term prophylaxis
may be needed in certain situations to prevent
rebleeding.
4 Intensive on-demand therapy may be appropriate
for the management of ICH and for certain
joint, muscle, and other bleeding events in pa-
tients with severe haemophilia A who are not on
prophylaxis.
Conclusion
The recurrent episodes of haemarthrosis that char-
acterize severe haemophilia A result in progressive
joint damage and eventually lead to significant
disability and impaired QOL. Prevention of bleeding
is the goal of modern therapy. Prophylaxis is the
most effective strategy for optimizing outcomes in
patients with severe haemophilia A. Primary pro-
phylaxis can prevent the development of arthropa-
thy, protect against other serious bleeding events,
and allow patients to live full, active lives. Depending
on when it is started, secondary prophylaxis may
provide many of the same benefits as primary
Table 6. Summary of the consensus recommendations for FVIII prophylaxis.
Recommendations for primary prophylaxis
d Prophylaxis should be initiated in all patients with severe haemophilia A before 2 years of age and prior to clinically evident joint
bleeding or after no more than a few joint haemorrhages (to establish the bleeding phenotype)
Recommendations for secondary prophylaxis
d In patients with severe haemophilia A in whom primary prophylaxis has been delayed, secondary prophylaxis should be initiated as
soon as possible, even after the onset of joint damage. It is never too late to start
d Secondary prophylaxis should be considered in patients with moderate haemophilia A who experience frequent joint bleeds
Recommendations for the prophylaxis dosing regimen
d Optimal prophylaxis requires the administration of FVIII 25–50 IU kg)1 three times weekly or every other day instituted before the
onset of frequent bleeding
d In certain cases, individualized dosing regimens that provide adequate prophylactic coverage can be considered in an effort to reduce
FVIII consumption, improve adherence, and enhance the adoption of prophylaxis
Recommendations for measuring prophylaxis outcomes
d Objective assessments of musculoskeletal status and health-related QOL should be a part of any effort to evaluate outcomes in patients
receiving prophylaxis
Recommendations for overcoming barriers to prophylaxis
d Consider an escalating-dose regimen when initiating prophylaxis to minimize the need for CVADs in young children
d AVF are an option for venous access in some children (e.g., those who have experienced repeated CVAD failure)
d Intermediate- and tailored-dose regimens may reduce costs while providing therapeutic benefits similar to those of full-dose pro-
phylaxis
d Provide patients and families with on-going education and support to facilitate their long-term commitment to prophylaxis
Recommendations for other preventive infusion strategies
d Primary or secondary prophylaxis is always preferred for patients with severe haemophilia A
d Limited prophylaxis to prevent bleeding in specific situations may require 100% correction to completely prevent bleeding
d Weeks, if not months, of short-term prophylaxis may be needed in certain situations to prevent rebleeding
d Intensive on-demand therapy may be appropriate for the management of ICH and for certain joint, muscle, and other bleeding events
in patients with severe haemophilia A who are not on prophylaxis
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prophylaxis, although it cannot reverse joint damage
that has already occurred.
The full-dose Malmö and intermediate dose Dutch
prophylactic regimens have been successfully used
for decades. However, individualized prophylaxis
that takes into consideration interpatient variability
in bleeding patterns and FVIII pharmacokinetics can
avoid overtreatment; reduce factor consumption;
lower treatment costs; and possibly, minimize the
need for CVADs. As a result, some of the barriers to
prophylaxis utilization may be overcome.
Because of the life-long risk of joint and other
bleeding events in patients with severe haemophilia
A, prophylaxis should be continued ideally into
adulthood to maintain the benefits achieved in
childhood. However, difficulties in transitioning to
adult care cause some patients to stop treatment. For
these individuals, limited prophylaxis and aggressive
on-demand therapy are alternative infusion strategies
that may prevent bleeding episodes or reduce bleed-
ing-related complications.
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